Kidney cancer surgery is performed as either partial (kidney-sparing) or radical nephrectomy, depending on tumour size and stage. Laparoscopic and robotic surgical options enable a minimally invasive approach with faster recovery.
Kidney cancer surgery (nephrectomy) is the surgical treatment of localised renal tumours. According to European Association of Urology (EAU) guidelines, it is performed using one of two approaches: partial nephrectomy (kidney-sparing) or radical nephrectomy (removal of the entire kidney). Surgical techniques include open, laparoscopic, and robotic surgery.
Prof. Dr. Özkan Onuk ile görüşün
| Detail | Information |
|---|---|
| Procedure | Nephrectomy (Partial or Radical) |
| Surgeon | Prof. Dr. Özkan Onuk — Urologist |
| Clinic | Urologica, Istanbul, Turkey |
| Surgery Duration | 2–4 hours (varies by technique) |
| Anaesthesia | General anaesthesia |
| Hospital Stay | 3–5 days |
| Recovery Time | 4–6 weeks |
| Accreditation | Turkish Urology Association and EAU standards |
| Pricing | Confirmed during your consultation |
| Contact | WhatsApp: +90 541 123 06 03 |
Kidney cancer surgery is the surgical removal of malignant tumours identified in the kidney.
Also known as renal cell carcinoma (RCC), kidney cancer accounts for the vast majority of renal tumours in adults. Surgery is the primary treatment with curative potential for localised kidney cancer.
Kidney tumour surgery is performed using two main techniques. Partial nephrectomy — also referred to as kidney-sparing surgery — involves removing the tumour along with a margin of healthy surrounding tissue, while preserving the remaining kidney. This approach is preferred particularly for small renal tumours (stage T1a and T1b). Radical nephrectomy involves removal of the entire kidney together with the surrounding fatty tissue and, where indicated, the adrenal gland.
Kidney cancer surgery can today be performed using open, laparoscopic, or robotic techniques. Robotic kidney surgery offers significant advantages in terms of precise dissection and kidney preservation, particularly in partial nephrectomy. The choice of surgical technique is determined by tumour size, location, the patient’s general condition, and the surgeon’s experience.
According to European Association of Urology (EAU) guidelines, partial nephrectomy should be performed wherever possible for renal tumours smaller than 7 cm (stage T1). This approach is critically important for the long-term preservation of kidney function. Prior to surgery, detailed staging assessment is carried out using computed tomography (CT) or magnetic resonance imaging (MRI).
Kidney cancer surgery is used to treat renal masses identified on imaging. The decision to operate is made following assessment of the tumour’s characteristics, the patient’s general health, and individual factors.
The main indications for kidney cancer surgery are: solid renal masses with features suspicious for malignancy on imaging, biopsy-confirmed kidney cancer, renal masses that are growing or symptomatic, and patients for whom active surveillance is not appropriate. Surgical treatment is considered the priority approach for suspicious masses identified in young and otherwise healthy patients.
Partial nephrectomy (kidney-sparing surgery) is preferred in the following situations: tumours smaller than 7 cm (stage T1), solitary kidney, bilateral (both-sided) renal tumours, individuals with chronic kidney disease, and hereditary kidney cancer syndromes. Radical nephrectomy is indicated for large tumours (generally over 7 cm), tumours that are anatomically unsuitable for partial nephrectomy, and locally advanced disease.
Treatment planning is determined through a multidisciplinary approach, with each patient’s case assessed individually. During your consultation with Prof. Dr. Özkan Onuk, tumour characteristics, surgical options, and expected outcomes will be discussed in detail.
Kidney cancer surgery cannot be performed in certain situations, and alternative treatment approaches may be preferred. Surgical contraindications are classified as absolute or relative.
Absolute contraindications include uncorrectable coagulopathy (clotting disorders), uncontrolled severe infection, and patients unfit for general anaesthesia. In cases of widespread metastatic disease, the benefit of surgery may be limited and systemic therapies take priority.
Relative contraindications include: elderly patients with significant co-morbidities, severe cardiopulmonary disease, patients at high surgical risk, and individuals with limited life expectancy. In these patients, alternative approaches such as active surveillance, ablation therapies (radiofrequency ablation, cryoablation), or stereotactic radiotherapy may be considered.
For small renal tumours — particularly those under 4 cm — active surveillance may be appropriate in elderly patients or those with significant co-existing conditions. In this approach, the tumour is monitored with regular imaging, and treatment planning is reassessed if growth or change is observed.
Each patient’s case is addressed individually, and the most appropriate treatment approach is determined following multidisciplinary evaluation.
Kidney cancer surgery can be performed using three different surgical approaches. Each technique has its own advantages and disadvantages.
| Feature | Open Surgery Traditional |
Laparoscopic Minimally Invasive |
Robotic Surgery Advanced Technology |
|---|---|---|---|
| Incision Size | 15–20 cm | 3–4 small incisions (0.5–1 cm) | 4–5 small incisions (0.5–1 cm) |
| Surgery Duration | 2–3 hours | 2–4 hours | 2–4 hours |
| Blood Loss | Greater | Less | Less |
| Hospital Stay | 5–7 days | 2–4 days | 2–4 days |
| Recovery Time | 6–8 weeks | 3–4 weeks | 3–4 weeks |
| Pain Level | High | Low–moderate | Low–moderate |
| Partial Nephrectomy | Feasible | Technically challenging | Ideal |
| Visualisation | Direct view | 2D camera | 3D HD imaging |
Open surgery is preferred for large or complex tumours, cases involving venous involvement, or situations where minimally invasive surgery is not appropriate. The surgeon can directly palpate the tissue and benefits from a wide operative field.
Laparoscopic surgery is widely used, particularly for radical nephrectomy. Smaller incisions reduce post-operative pain and accelerate recovery. However, in partial nephrectomy, the technical demands of the approach require considerable surgical experience.
Robotic surgery is the preferred approach, especially for partial nephrectomy. Three-dimensional visualisation, high magnification, and 360-degree instrument articulation enable precise dissection and reconstruction. Ischaemia time (the period during which blood flow to the kidney is interrupted) can be minimised, which offers a significant advantage for preserving kidney function.
The choice of surgical technique is determined by tumour characteristics, the patient’s anatomy and general condition, the surgeon’s experience, and the available technological infrastructure.
Outcomes following kidney cancer surgery vary according to tumour stage, surgical approach, and the patient’s general condition. Setting realistic expectations is an important part of the treatment process.
For localised kidney cancer (stage T1–T2), surgical treatment achieves high cure rates. Oncological outcomes following surgery for early-stage tumours are very favourable, and the majority of patients achieve long-term disease-free survival. In locally advanced disease (stage T3–T4), prognosis varies depending on tumour characteristics and surgical margin status.
Preserving kidney function after partial nephrectomy is one of the primary goals of surgery. Following a successful partial nephrectomy, the remaining kidney tissue continues to function normally, and the long-term risk of chronic kidney disease is reduced. After radical nephrectomy, life with a single kidney is possible; where the contralateral kidney is healthy, compensatory mechanisms take over.
Regular follow-up after surgery is an integral part of kidney cancer management. The follow-up protocol includes imaging studies (CT, MRI), blood tests, and physical examination. The frequency and duration of follow-up are determined by the tumour’s risk classification. Less frequent intervals are sufficient for low-risk tumours, while high-risk patients require more intensive and longer-term surveillance.
Individual outcomes may vary. During your consultation with Prof. Dr. Özkan Onuk, expectations specific to your situation will be discussed in detail.
A thorough preparation process takes place before kidney cancer surgery. Pre-operative assessment includes review of imaging studies, blood tests, cardiological evaluation, and anaesthetic consultation. Patients must fast from midnight before the procedure, and any blood-thinning medications must be stopped a specified number of days in advance.
On the day of surgery, the patient is placed under general anaesthesia. For robotic or laparoscopic surgery, the patient is positioned in a lateral decubitus (side-lying) position, and trocars are inserted through small incisions in the abdominal wall. The abdominal cavity is insufflated with carbon dioxide gas to create the working space.
In partial nephrectomy, the surgical procedure involves the following steps: mobilisation of the kidney and identification of its vessels; localisation of the tumour under ultrasound guidance; clamping of the renal artery (ischaemia); excision of the tumour with a clear surgical margin; repair of the collecting system; suturing of the renal parenchyma; and achievement of haemostasis. Minimising ischaemia time is critically important for preserving kidney function.
In radical nephrectomy, the renal vessels are ligated, the kidney is mobilised together with the surrounding tissue, and removed within an endoscopic specimen bag. Regional lymph nodes are also removed where indicated.
At the end of the procedure, the incisions are closed and the patient is transferred to intensive care or a surgical ward. The removed tissue is sent for pathological examination to confirm the definitive diagnosis and staging.
As with any surgical procedure, kidney cancer surgery carries certain risks. Complication rates are related to the surgeon’s experience, the technique selected, and the patient’s general condition.
| Complication | Frequency | Notes |
|---|---|---|
| Bleeding | Rare | May require blood transfusion or reoperation |
| Infection | Rare | Wound site or urinary tract infection |
| Urinary leakage | Rare (partial) | Related to collecting system injury |
| Loss of kidney function | Variable | Transient or permanent, depending on ischaemia time |
| Adjacent organ injury | Very rare | Spleen, bowel, pancreas, liver |
| Thromboembolic events | Rare | Deep vein thrombosis, pulmonary embolism |
| Conversion to open surgery | Rare | In cases commenced with a minimally invasive approach |
Complications specific to partial nephrectomy include urinary leakage (urinoma), post-operative bleeding, arteriovenous fistula, and pseudoaneurysm. Most of these complications can be managed with conservative treatment or minimally invasive interventions.
To reduce the risk of complications, the following are important: pre-operative optimisation (nutritional status, management of co-existing conditions), performance of the procedure by an experienced surgeon and team, appropriate patient selection, and close post-operative monitoring.
Possible complications and individual risk factors are discussed in detail during the consultation.
Recovery following kidney cancer surgery varies according to the surgical technique chosen and the patient’s general condition. Recovery with minimally invasive approaches is faster compared to open surgery.
First 24–48 hours (In hospital): The patient is monitored closely in intensive care or a surgical ward. Pain management, fluid balance monitoring, early mobilisation, and breathing exercises are important elements of this period. A urinary catheter and any surgical drains are in place and removed according to clinical progress.
First week (After discharge): Light walking is encouraged. Heavy lifting and strenuous activity are not permitted. Wound care instructions must be followed and prescribed medications taken regularly. A high-fibre diet and adequate fluid intake are recommended to prevent constipation.
Weeks 2–4: Daily activities are gradually increased. Driving is generally possible after 2–3 weeks. Return to desk-based work can be planned during this period. An outpatient appointment is scheduled for wound review.
Weeks 4–6: Return to normal activities is complete. Physically demanding work and sport can be resumed during this period. Pathology results are reviewed and a follow-up plan is established.
Long-term follow-up: Regular reviews are the cornerstone of kidney cancer management. Reviews include imaging studies, kidney function tests, and physical examination. The follow-up protocol is individualised according to the tumour’s risk classification.
If any concerns arise during recovery — such as fever, severe pain, wound discharge, or inability to urinate — contact your doctor promptly.
Prof. Dr. Özkan Onuk is a practising academic physician specialising in urology and urological oncology.
Prof. Dr. Özkan Onuk serves as a faculty member in the Department of Urology at Biruni University Faculty of Medicine. He has extensive clinical experience in kidney cancer surgery, minimally invasive urological surgery, and uro-oncology.
Academic Position: Faculty Member, Department of Urology, Biruni University Faculty of Medicine
Areas of Expertise:
Memberships:
Clinical Practice: Prof. Dr. Onuk provides consultations and surgical treatment for kidney cancer and uro-oncology conditions at Urologica Clinic in Istanbul. Each patient is assessed individually, and treatment plans are developed in accordance with current clinical guidelines and the patient’s specific circumstances.
To learn more about kidney cancer surgery and arrange a personalised assessment, you can book a consultation with Prof. Dr. Özkan Onuk.
During your consultation, your medical history will be reviewed, a physical examination will be performed, and treatment options will be discussed. You will receive detailed information about your diagnosis, surgical options, and what to expect throughout the process. Your personal questions will be answered and your expectations carefully considered.
Contact:
📱 WhatsApp: +90 541 123 06 03 📧 Email: Urologica.tr@gmail.com 📍 Location: Urologica, Istanbul, Turkey
The information on this page is provided for informational purposes only and does not substitute professional medical advice. Always consult a qualified physician regarding any medical condition. Individual outcomes may vary. Prof. Dr. Özkan Onuk and Urologica accept no responsibility for decisions made based on the information provided here. This content has been prepared in accordance with the regulations of the Turkish Ministry of Health.
Medically reviewed by: Prof. Dr. Özkan Onuk, Faculty Member, Department of Urology Last updated: February 2026 | Next review: May 2026Safe, expert treatment with an experienced urological oncology team and a multidisciplinary approach.
Urologist | Clinical Director
Partial nephrectomy removes the tumour while preserving healthy kidney tissue.
Laparoscopic and robotic surgical options for less pain and faster recovery.
Coordinated treatment planning with medical oncology, radiation oncology, and pathology specialists.
Regular post-operative imaging and reviews for ongoing recurrence surveillance.
Böbrek ve mesane sağlığı alanında sunduğumuz diğer tedavi yöntemlerini keşfedin.
ESWL, URS ve PNL yöntemleri ile böbrek taşlarının güvenli ve etkili tedavisi.
Detaylı BilgiMesane tümörlerinde TUR-MT, BCG tedavisi ve radikal sistektomi seçenekleri.
Detaylı BilgiSık idrara çıkma ve ani sıkışma hissinde ilaç tedavisi ve botoks enjeksiyonu seçenekleri.
Detaylı BilgiThe most common questions about kidney cancer surgery, answered.
Still have questions? Ask us anything during a free consultation.
Ask Us on WhatsAppSpeak confidentially with Prof. Dr. Özkan Onuk, get your questions answered, and together we'll build the treatment plan that's right for you.
WhatsApp'tan Yazin